title: Canadian whistleblower row prompts broader code of conduct.
authors.forename: D
authors.initials: D
authors.lastname: Spurgeon
mesh_terms: D035843:Biomedical Research; D002170:Canada; D016265:Conflict of Interest; D000077543:Deferiprone; D030881:Disclosure; D004345:Drug Industry; D004992:Ethics, Medical; D006776:Hospitals, Pediatric; D006801:Humans; D008099:Liver / Q000187:drug effects; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use; D012106:Research / Q000592:standards; D012109:Research Support as Topic; D015871:Scientific Misconduct; D013789:Thalassemia / Q000188:drug therapy; D014342:Truth Disclosure; D035642:Whistleblowing
chemical_list: D011728:Pyridones; D000077543:Deferiprone